Lilly brings drug development to the classroom with new college course offering
The online drug development course provides an interactive platform for students to explore the fundamental principles of drug development, learn about the regulatory environment that govern the biopharmaceutical industry, and identify the roles of key stakeholders.
Graduate students across the country, with an interest in health care and medical research, will soon have the opportunity to learn about a lesser-known area of patient care — the drug discovery and development process. Eli Lilly has collaborated with 10 leaders from academic institutions to create an elective graduate level course, "Making Medicines: The Process of Drug Development." Lilly will formally unveil the eLearning course at the American Osteopathic Association scientific conference in Orlando, Fla., 17–21 October, and launch its pilot program with academic partners beginning in 2016.
The online drug development course provides an interactive platform for students to explore the fundamental principles of drug development, learn about the regulatory environment that govern the biopharmaceutical industry, and identify the roles of key stakeholders, including physicians, who develop, investigate, and regulate biopharmaceutical products. The course includes seven chapters that contain various elements, such as expert videos from the perspective of the FDA and NIH, knowledge checks, case studies and competency tests.
"We identified a knowledge gap surrounding the biopharmaceutical industry and its drug discovery and development process," said Yolanda Johnson-Moton, Director, External Relations Medical Affairs, Lilly USA, "and set out to find a solution that would further education and awareness. Our unified focus is on creating better patient outcomes, and the healthcare providers of tomorrow are an integral part of the process."
"The 'Making Medicines: The Process of Drug Development' course allows students to engage in a self-directed learning process to become familiar with drug discovery and development," said Dr Marc Kahn, Senior Associate Dean, Tulane University School of Medicine. "Students will obtain useful knowledge in a self-paced setting and will apply that knowledge in a series of assessment exercises. I plan to use this course as an elective for senior medical students who want to learn more about drug development, the FDA and the biopharmaceutical industry."
The launch of the course comes shortly after the introduction of Lilly's Medical Student Rotation Program, a 4-week experiential learning program at their Indianapolis headquarters, where third- and fourth-year medical students familiarize themselves with the biopharmaceutical industry and its role in the practice of medicine through real-world projects and workshops. Future healthcare providers, who will be dependent on new medicines for their patients, will benefit from learning about the discovery and approval process.
"These student programs offer Lilly the opportunity to bring forth its longstanding focus on education and build collaborative relationships," said Johnson-Moton. "The Making Medicines: The Process of Drug Development" course provides flexibility to fit within existing academic programs. Our goal is reach more students with an interest in medical research and help provide a balanced perspective on the process and rigor behind drug development."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance